# Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

> **NCT04040322** · PHASE3 · COMPLETED · sponsor: **Civi Biopharma, Inc.** · enrollment: 198 (actual)

## Conditions studied

- Raynaud's Phenomenon Secondary to Systemic Sclerosis

## Interventions

- **DRUG:** Placebo IV infusion
- **DRUG:** Iloprost Injection, for intravenous use

## Key facts

- **NCT ID:** NCT04040322
- **Lead sponsor:** Civi Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-14
- **Primary completion:** 2021-06-09
- **Final completion:** 2021-06-09
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04040322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04040322, "Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04040322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*